Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II neoadjuvant fruquintinib + sintilimab + chemotherapy with nutritional support for digestive system tumors
ChiCTR2400082413Phase 2Recruiting
- Sponsor
- Second Hospital of Lanzhou University
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fruquintinib, sintilimab, oxaliplatin, capecitabine and tegafur + gimeracil + oteracil in gastric cancer (GC), esophagogastric junction cancer, colon cancer and 1 more, sponsored by Second Hospital of Lanzhou University. Primary endpoint: Pathological complete response rate. Started Mar 2024; status: recruiting.
02
Drugs
fruquintinibsintilimaboxaliplatincapecitabinetegafur + gimeracil + oteracil
03
Conditions
gastric cancer (GC)esophagogastric junction cancercolon cancergastrointestinal cancer
Beyond the preview
Go deeper on ChiCTR2400082413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082413.